Atlantic Diagnostic Laboratories (ADL) under an exclusive U.S. licensing agreement with Metabolomic Technologies Inc. (MTI) will begin distributing PolypDx, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer.
With early detection in the adenomatous polyp stage, the cancer may be preventable, saving lives and reducing treatment costs.
In a Canada-based clinical trial of nearly 1,000 patients, PolypDx demonstrated significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps. Once screened, patients presenting a risk of adenomatous polyps can be directed to a colonoscopy, during which the adenomatous polyps can be completely and safely removed, thus preventing the progression into colorectal cancer.
PolypDx, the flagship product of Edmonton-Alberta-based MTI, which signed a multi-million dollar agreement with ADL giving them the exclusive licensing and distribution rights to bring PolypDx into the U.S. market.
ADL is a full service clinical laboratory with headquarters in the suburbs of Philadelphia providing microbiology, chemistry, toxicology, immunology, virology and molecular testing in 11 states, including Pennsylvania, New Jersey, Connecticut, New York, Delaware, Maryland, Virginia, Florida, Ohio, Kentucky and West Virginia, along with the District of Columbia.